Why is Hims & Hers Health stock rallying today?

Shares of Hims & Hers Health rose 5.7% in mid-day trading after the company unveiled a direct partnership with Eli Lilly to distribute the drugmaker’s weight-loss therapies — the injectable Zepbound and the newly launched oral pill Foundayo — through its telehealth platform at self-pay prices of $299 and $149 per month, respectively. The agreement streamlines the patient experience by allowing users to consult a licensed provider, obtain a prescription, and receive FDA-approved medication at home entirely within the Hims & Hers digital ecosystem, eliminating the need to navigate to Lilly’s separate cash-pay portal.

The Lilly deal is strategically significant because it mirrors a similar arrangement Hims & Hers struck with Novo Nordisk in March 2026 to distribute Wegovy and Ozempic, meaning the platform now carries branded GLP-1 offerings from both of the dominant players in the obesity drug market. This reflects a deliberate business pivot by the company, which earlier this year moved away from selling compounded versions of obesity medications in favor of offering branded, FDA-approved alternatives. With Q3 2026 earnings scheduled for November 9 — where analysts expect revenue of roughly $892.88 million — investors are also positioning ahead of what could be a pivotal update on the company’s GLP-1 strategy.

The broader market provided a constructive backdrop for today’s move. The S&P 500 gained +0.59% and the Nasdaq climbed +1.17%, staging a partial recovery after Thursday’s brutal AI-driven sell-off that erased trillions in market value and pushed the Nasdaq into correction territory. A stronger-than-expected October jobs report, showing the U.S. economy added 165,000 jobs, helped stabilize sentiment, and the Federal Reserve’s policy statement later in the day was also on investors’ radar.

Together, a high-profile corporate partnership that meaningfully expands Hims & Hers’ addressable market in the fast-growing obesity drug category, combined with a recovering broader market and pre-earnings positioning, drove shares well off their 52-week low of $13.74 — though they remain far below the 52-week high of $42.70, leaving room for further recovery if the Q3 earnings report delivers.